RaQualia Pharma Inc. To Postpone IPO

RaQualia Pharma Inc., a PE-backed bio venture firm, announced that RaQualia has decided to postpone its pending public offering due to the extraordinary market conditions brought on by the earthquake. There will be a discontinuance of the sale and issuance of stock this time. RaQualia was founded in 2008 via EBO (Employee Buy-Out) from Pfizer Inc., a global pharmaceutical firm, with NIF SMBC Venture Capital and Coller Capital, a European private equity firm. RaQualia will continue its efforts to list on the JASDAQ Growth Market in the near future with the cooperation of The Daiwa Securities Capital Markets Co., Ltd., an investment banking unit of Daiwa Securities Group,.